Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hi-Tech sales down despite OTC growth

This article was originally published in The Tan Sheet

Executive Summary

The Amityville, N.Y.-based manufacturer reports a 69 percent first-quarter leap in OTC sales, benefited by the March acquisition of Mag-Ox magnesium supplements (1"The Tan Sheet" July 19, 2010, In Brief). Sales in Hi-Tech Pharmacal's Health Care Products division, which markets OTCs, grew to $2 million in the quarter ended July 31. Overall sales, however, were $40.4 million, down 7 percent from last year's period of unusually high demand for cold and flu products due to fears of H1N1 flu and due to the suspended sale of certain unapproved Rx products, the company said Sept. 8. Hi-Tech reports net income of 67 cents per diluted share, down from 73 cents

You may also be interested in...

Hi-Tech rides Mag-Ox growth

The recently acquired line of magnesium supplements helps Hi-Tech Pharmacal's Health Care Products division increase sales 17.4 percent to $2.7 million in its fiscal 2010 fourth quarter and 11.9 percent to $11.3 million in the full year ended April 30. Annual sales of Mag-Ox products reached $3.4 million prior to Hi-Tech's March acquisition. The firm plans to increase distribution and extend the brand in the new fiscal year, CEO David Seltzer said July 13 (1"The Tan Sheet" March 8, 2010, In Brief). Amityville, N.Y.-based Hi-Tech, which markets to the diabetic health segment, also attributed OTC growth to increased sales of its Diabetic Tussin and Multi-betic products. The company reported overall net sales of $163.7 million - up 50.7 percent - and net income of $31.1 million - up 217 percent - for fiscal 2010

House Of Representatives Concerned Over Complex Generics

The Committee on Energy and Commerce of the US House of Representatives has requested a set of documents from the FDA in order to assess whether the agency is doing enough to address the challenge of approving complex generics within its existing authorities or whether additional authority is needed.

Stockwatch: Earnings Season Catches An Early Cold As Coronavirus Sweeps In

As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.







Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts